Literature DB >> 27089010

SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY EVALUATION OF RETINAL STRUCTURE IN PATIENTS WITH SUSACS SYNDROME.

Aniruddha Agarwal1, Mohamed Soliman, Salman Sarwar, Mohammad Ali Sadiq, Diana V Do, Quan Dong Nguyen, Yasir Jamal Sepah.   

Abstract

PURPOSE: To report spectral-domain optical coherence tomography (SD-OCT) features in patients diagnosed with Susacs syndrome.
METHODS: Clinical report of two cases.
RESULTS: Spectral-domain optical coherence tomography was performed in two patients diagnosed with Susacs syndrome. Both the patients had normal macular perfusion on fluorescein angiography (FA). However, SD-OCT revealed bilateral, temporal macular atrophy with disorganization and thinning of the retinal layers. The outer plexiform layer showed nodularity and waviness suggestive of ischemic swelling of the bipolar cells.
CONCLUSION: Retinal structural changes in Susacs syndrome have not been described earlier. Spectral-domain optical coherence tomography may be more sensitive than fluorescein angiography in detecting microstructural retinal alterations in various layers, especially in apparently perfused retina. These findings may provide an insight into the pathogenesis of Susacs syndrome.

Entities:  

Mesh:

Year:  2017        PMID: 27089010     DOI: 10.1097/ICB.0000000000000308

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  2 in total

1.  Optical coherence tomography angiography findings in Susac's syndrome: a case report.

Authors:  Rodolfo Mastropasqua; Lisa Toto; Alfonso Senatore; Alessandro D'Uffizi; Piergiorgio Neri; Cesare Mariotti; Marica Tina Maccarone; Luca Di Antonio
Journal:  Int Ophthalmol       Date:  2017-07-20       Impact factor: 2.031

2.  Multimodal Imaging in Susac Syndrome: A Case Report and Literature Review.

Authors:  Simone Alex Bagaglia; Franco Passani; Giovanni William Oliverio; Leandro Inferrera; Feliciana Menna; Alessandro Meduri; Cosimo Mazzotta
Journal:  Int J Environ Res Public Health       Date:  2021-03-26       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.